SecBot SecBot
Insider Cluster (4 insiders) ·Filed Apr 21, 2026

HEPA

Hepion Pharmaceuticals, Inc.
MIXED
Impact 5/10
Horizonweeks Processed6mo ago
Insider cluster: 4 insiders, $0.3M total
Actionable Insight ◆ Mixed

The insider buying provides a short-term floor, but the broader picture of CEO departure and dilutive financing suggests continued risk. Watch for additional funding needs or operational updates; a reverse split or further dilution could pressure the stock.

DirectionMixed
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
HEPA ▼ -34.93% at T+60d
NEUTRAL call -34.93% · α vs SPY -38.92% · entry $0.0700 → $0.0455
Entry = T+0 close
Apr 27, 2026
via day close
T+1d
+1.43%
call +1.43% · α +1.44%
$0.0710
settled 6mo ago
T+5d
-22.86%
call -22.86% · α -24.55%
$0.0540
settled 6mo ago
T+20d
+7.14%
call +7.14% · α +1.67%
$0.0750
settled 5mo ago
T+60d
-34.93%
call -34.93% · α -38.92%
$0.0455
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Four Hepion insiders, including the Interim CEO and Executive Chairman, purchased $350K in shares at $0.04 on April 21, coinciding with a dilutive private placement announced April 22. While the insider buying signals confidence, it follows the CEO's resignation and a $700K capital raise, indicating financial distress.

Key Financial Metrics

Direction
buying
Total Value
$350.0K
Insiders
4

Key Facts

  • 4 insiders bought 8.75M shares total for $350K at $0.04/share on 4/21/2026.
  • Purchases align with a private placement of 17.5M shares at $0.04 raising $700K (8-K filed 4/22).
  • CEO resigned effective 4/13/2026 with a separation agreement (8-K filed 4/14).
  • Stock trades on OTC QB at ~$0.04, market cap likely under $5M.

Financial Impact

Insider purchases total $350K, representing material ownership increase for a micro-cap, but part of a $700K dilutive offering.

dilutioninsider ownershipcash position

Risk Factors

  • Further dilution from additional offerings.
  • Lack of revenue and clinical trial progress.
  • Low stock price may lead to delisting from OTC.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-HEPA-1777325621452
7 reports for HEPA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HEPA — sortable, filterable
TypeNow
Oct 26, 2026
today
SC 13D
NEUTRAL ★ 5/10
—awaiting T+20——
Oct 21, 2026
5d ago
SC 13G/A
NEUTRAL ★ 3/10
$0.1350awaiting T+20—$0.1281 (−5.11%)
Oct 9, 2026
17d ago
8-K
MIXED ★ 6/10
$0.1240awaiting T+20—$0.1281 (+3.31%)
Sep 28, 2026
28d ago
8-K
BEARISH ★ 6/10
$0.0800 $0.1281▼ −60.13%▼ −60.16%$0.1281 (−60.12%)
Aug 12, 2026
10w ago
Insider Cluster
BULLISH ★ 6/10
$0.0700 $0.0550▼ −21.43%▼ −19.68%$0.1281 (+83.00%)
Apr 21, 2026
27w ago
Insider Cluster
MIXED ★ 5/10
$0.0700 $0.0750▲ +7.14%▲ +1.67%$0.1281 (+83.00%)
Apr 21, 2026
27w ago
Insider Cluster
MIXED ★ 6/10
$0.0620 $0.0750▲ +20.97%▲ +16.01%$0.1281 (+106.61%)
Showing 7 of 7

US Market Status

Market Closed — Opens Wed (13h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026